Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes

Received 31 January 2006; received in revised form 10 September 2006; accepted 6 October 2006. published online 24 November 2006.

Abstract

To investigate the effects of sulfonylurea receptor 1 (SUR1) exon 33 (TCC→GCC, S1369A) polymorphism on responsiveness to gliclazide. About 115 patients with type 2 diabetes were treated with gliclazide for 8 weeks. SUR1 genotypes were tested by Taqman-PCR. After gliclazide treatment, there was association between T/G polymorphism and decrease of HbA1c. G carriers were more sensitive to gliclazide and the decrease of HbA1c was more significant than TT genotype (TT, 0.76%±1.70%; TG+GG, 1.60%±1.39%, P=0.044). The polymorphism of SUR1S1369A was associated with the therapeutic efficacy of gliclazide.

Keywords: Type 2 diabetes, Polymorphism, Gliclazide

a Department of Endocrinology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China

b Institute of Biomedicine, Anhui Medical University, Hefei 230032, China

Corresponding author at: c/o Mr. Wei Sun, 145 Nan-Tong Street, School of Economics and Management, Harbin Engineering University, Harbin 150001, China.

PII: S0168-8227(06)00492-X

doi:10.1016/j.diabres.2006.10.021

5 of 22